Clinical Trials for Colon Cancer

A Phase I/Ib Trial of ProAgio, an Anti-avb3 Integrin Cytotoxin, in Combination With 5-fluorouracil , Irinotecan and Bevacizumab for Advanced/Metastatic Colorectal Cancer (ProAgio in CRC)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with untreated advanced/metastatic colorectal adenocarcinoma (ECOG 0–1), measurable disease, and adequate organ function receive ProAgio—an investigational pegylated peptide that targets integrin αvβ3 on cancer-associated fibroblasts and endothelial cells to induce apoptosis and remodel stroma—combined with FOLFIRI (irinotecan/infusional 5-FU) plus bevacizumab. Prior FOLFOX for adjuvant disease >1 year is allowed in expansion, while prior FOLFIRI or 5-FU–based therapy for metastatic disease is excluded.

ClinicalTrials.gov ID: NCT06867822

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 (CDH17) Chimeric Antigen Receptor (CAR) T Cell Therapy for the Treatment of Relapsed or Refractory Gastrointestinal Cancers

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with relapsed/refractory gastrointestinal cancers (gastric adenocarcinoma [CDH17+], colorectal adenocarcinoma, or well-differentiated mid/hindgut NETs) receive lymphodepleting fludarabine/cyclophosphamide followed by a single infusion of CHM-2101, an autologous third-generation CAR T therapy targeting cadherin-17. Single-arm dose escalation/expansion; bridging chemo allowed between leukapheresis and lymphodepletion.

ClinicalTrials.gov ID: NCT06055439

A Phase 1, Open-Label, Multicenter Study of INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with locally advanced/metastatic solid tumors harboring KRAS G12D (ECOG 0–1), including dedicated PDAC and CRC cohorts, receive INCB186748, an oral selective KRAS G12D inhibitor, as monotherapy or combined with cetuximab, gemcitabine/nab-paclitaxel, or modified FOLFIRINOX. Prior KRAS inhibitor exposure is excluded; combination cohorts in PDAC/CRC have line-specific limits (generally post-standard therapy; some PDAC cohorts allow ≤1 prior line).

ClinicalTrials.gov ID: NCT06818812

A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors or diffuse large B-cell lymphoma who have exhausted standard therapies, evaluating the investigational oral CBL-B inhibitor NX-1607 (which enhances antitumor immunity by blocking a negative regulator of immune cell activation) as monotherapy or in combination with paclitaxel. Eligible tumor types include ovarian, gastric, head and neck, melanoma, NSCLC, prostate, mesothelioma, triple-negative breast, urothelial, cervical, microsatellite-stable colorectal cancer, and DLBCL/Richter transformation.

ClinicalTrials.gov ID: NCT05107674

First-in-Human Phase I Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with metastatic solid tumors (such as pancreatic, colorectal, and breast cancers) who have progressed after standard therapies, as well as adolescents (12–17 years) with solid tumors lacking standard options (excluding rhabdomyosarcoma), to receive oral metarrestin, a first-in-class small molecule that targets the perinucleolar compartment to disrupt ribosome biogenesis and inhibit metastasis.

ClinicalTrials.gov ID: NCT04222413

A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with advanced, measurable solid tumors (including separate cohorts for breast, pancreatic, or gastric cancer) who have progressed after standard therapy, testing Minnelide—a prodrug of triptolide that inhibits HSP70 with downstream anti-oncogenic effects—given alone or in combination with protein-bound paclitaxel. Patients must have good performance status and adequate organ function.

ClinicalTrials.gov ID: NCT03129139

A Phase Ia/Ib, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of RSC-1255 in Patients With Advanced Solid Tumor Malignancies

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors who have exhausted standard therapies and provides investigational monotherapy with RSC-1255, an oral small-molecule inhibitor of V-ATPase targeting both mutant and wild-type RAS, with enhanced potency against KRAS-G13D and KRAS-G12V mutations. All participants receive RSC-1255, and no control arm is included.

ClinicalTrials.gov ID: NCT04678648